- Home
- BCYC vs TYRA Comparison
BCYC vs TYRA Comparison
Compare BCYC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- TYRA
- Stock Information
- Founded
- BCYC 2009
- TYRA 2018
- Country
- BCYC United Kingdom
- TYRA United States
- Employees
- BCYC N/A
- TYRA N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- BCYC Health Care
- TYRA Health Care
- Exchange
- BCYC Nasdaq
- TYRA Nasdaq
- Market Cap
- BCYC 492.1M
- TYRA 571.9M
- IPO Year
- BCYC 2019
- TYRA 2021
- Fundamental
- Price
- BCYC $6.90
- TYRA $12.30
- Analyst Decision
- BCYC Buy
- TYRA Strong Buy
- Analyst Count
- BCYC 11
- TYRA 8
- Target Price
- BCYC $22.91
- TYRA $31.00
- AVG Volume (30 Days)
- BCYC 233.2K
- TYRA 235.9K
- Earning Date
- BCYC 10-30-2025
- TYRA 11-06-2025
- Dividend Yield
- BCYC N/A
- TYRA N/A
- EPS Growth
- BCYC N/A
- TYRA N/A
- EPS
- BCYC N/A
- TYRA N/A
- Revenue
- BCYC $19,281,000.00
- TYRA N/A
- Revenue This Year
- BCYC N/A
- TYRA N/A
- Revenue Next Year
- BCYC $0.27
- TYRA N/A
- P/E Ratio
- BCYC N/A
- TYRA N/A
- Revenue Growth
- BCYC N/A
- TYRA N/A
- 52 Week Low
- BCYC $6.10
- TYRA $6.42
- 52 Week High
- BCYC $28.67
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- BCYC 39.17
- TYRA 56.45
- Support Level
- BCYC $6.84
- TYRA $11.70
- Resistance Level
- BCYC $7.32
- TYRA $12.55
- Average True Range (ATR)
- BCYC 0.36
- TYRA 0.68
- MACD
- BCYC 0.01
- TYRA -0.04
- Stochastic Oscillator
- BCYC 14.56
- TYRA 38.84
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.